CTIS2024-512737-33-00进行中（未招募）1 期
A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) - 1821-FSH-301
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Part A: 1. Patient will sign and date an ICF 2. Patients will have a diagnosis of FSHD1 or FSHD2 verified by genetic testing - Randomization will be stratified for FSHD1 to ensure that treatment allocation is balanced across FSHD repeat number categories (ie, 1 to 3 repeats versus 4 to 9 repeats). - Randomization will be stratified for FSHD2 to ensure that an equal number of patients will be allocated to treatment and placebo. 3. Patients will have a Clinical Severity Score of 2 to 4 (Ricci score; range 0 to 5) at screening. Patients who are wheelchair-dependent or dependent on walker or wheelchair for activities are not permitted to enroll in the study. 4. Patients with screening total RSA (Q1-Q4) without weight in the dominant UE assessed by RWS = 0.2 and = 0.7. 5. Willing and able to comply with scheduled visits, treatment plan and other study procedures 6. No contraindications to MRI 7. Patients (male and female) will be between the ages of 18 and 65 years at the time of consent, inclusive - A female patient is eligible to participate if she is of non-child bearing potential, defined as pre-menopausal females with a documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy; if she is postmenopausal, defined as no menses for 12 months without an alternative medical cause; OR - if of child-bearing potential, she is using a highly effective method for avoidance of pregnancy for the duration of dosing and until 90 days after the last dose of study drug - Male patients must agree to use one of the contraception methods. This criterion must be followed from the time of the first dose of study medication and until 90 days after the last dose of study drug Part B: 1. Patient completed 48 weeks of treatment during Part A. 2. Patient will sign and date an ICF. 3. Patient is willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures. 4. Patient agrees to the following methods of contraception: - Female patients of childbearing potential agree to continue using a highly effective method for avoidance of pregnancy for the duration of dosing and until 90 days after the last dose. - Male patients must agree to use one of the contraception methods listed in Section 5.5.1 of the protocol. This criterion must be followed from the time of the first dose of study medication and until 90 days after the last dose of study drug.
排除标准
- •Part A: 1. History of any illness or any clinical condition that might confound the results of the study or pose an additional risk in administering study drug to the patient. 2. Previously diagnosed cancer that has not been in complete remission for at least 5 years. Localized carcinomas of the skin and carcinoma in situ of the cervix that have been resected or ablated for cure are not exclusionary. 3. For patients who are on drug(s) or supplements that may affect muscle function or that are included in the list of drugs presented in Appendix 3 of the Protocol: pt must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study. 4. History of febrile illness within 5 days before the first study drug dose 5. Known active opportunistic or life-threatening infections including HIV and hepatitis B or C 6. Known active or inactive tuberculosis infection. 7. Current acute liver disease or chronic liver disease as defined by any of the following: current ALT =2 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN (unless participant has Gilbert's syndrome characterized by the combination of total bilirubin < 3 × ULN, direct bilirubin within the normal range and normal ALT and AST, or the presence of mutations in the UDP-glucuronosyltransferase 1 gene, indicative of Gilbert's syndrome); or Positive for hepatitis B or surface antigen; or Positive for hepatitis C antibody unless additional testing for hepatitis C viral RNA is negative, ALT is < 2 × ULN and total bilirubin is =1.5 × ULN, indicating inactive/resolved hepatitis C infection 8. Known severe renal impairment (defined as a glomerular filtration rate of < 30 mL/min/1.73 m2). 9. Standard 12-lead ECG demonstrating QTcF >450 msec for male patients and QTcF >470 msec for female patients at screening. If QTcF exceeds 450 msec for males or 470 msec for females, the ECG will be repeated 2 more times, and the average of the 3 QTcF values will be used to determine the patient's eligibility. 10. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s); or history or evidence of abnormal ECGs 11. Male patients with a female partner who is planning to become pregnant during the study or within 90 days after the last study drug dose, 12. Concomitant use of cytotoxic chemotherapy for cancer or known ongoing or anticipated use of chronic severe immunosuppressive agents. 13. Positive pregnancy test or known to be pregnant or lactating or planning to become pregnant during study drug administration and until 90 days after last dose 14. Any current mental condition (psychiatric disorder, senility or dementia) 15. Patient has any condition possibly affecting drug absorption 16. History of alcohol, analgesic/opioid, and/or illicit drug abuse, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (American Psychiatric Association, 2013), in the last 6 months before screening or a positive test for drugs of abuse at screening. Use of CBD/THC is permitted 17. Use of another IP within 30 days or 5 half-lives 18. Current or anticipated participation in a natural hx study. 19. Known hypersensitivity or intolerance to losmapimod or any of its excipients 20. Previous participation in a Fulcrum-sponsored FSHD losmapimod study 21. Anticipated inability to comply with any study procedures, study visits according to the visit schedule through 48 weeks.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644